Table 2—

PFT results in subjects with a baseline and at least one postbaseline PFT measurement

PFT parameterInhaled insulin
Subcutaneous insulin
Adjusted inhaled-subcutaneous difference in change from baseline at week 24 (95% CI)*
BaselineWeek 12Week 24BaselineWeek 12Week 24
n149140136149141142
FEV1 (l)2.840 ± 0.6692.765 ± 0.6512.789 ± 0.6652.980 ± 0.6832.915 ± 0.6482.910 ± 0.6440.000 (−0.048 to 0.048)
n149140136149141142
FVC (l)3.587 ± 0.8323.527 ± 0.8203.548 ± 0.8673.734 ± 0.9073.670 ± 0.8243.657 ± 0.8140.025 (−0.041 to 0.090)
n149134149139
TLC (l)5.717 ± 1.1675.730 ± 1.1965.837 ± 1.1905.786 ± 1.2400.044 (−0.080 to 0.168)
n146135147140
DLCO (ml · min−1 · mmHg−1)23.554 ± 5.24822.760 ± 5.65024.100 ± 5.44723.390 ± 5.501−0.403 (−1.166 to 0.360)
  • Data are means ± SD, unless noted otherwise.

  • *

    * For adjusted mean treatment group difference in change from baseline at week 24.